Corient Private Wealth LLC Grows Stock Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Corient Private Wealth LLC grew its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 1.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,067 shares of the company’s stock after buying an additional 381 shares during the quarter. Corient Private Wealth LLC’s holdings in HCA Healthcare were worth $11,724,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HCA. GSA Capital Partners LLP purchased a new position in shares of HCA Healthcare in the third quarter valued at $567,000. Quest Partners LLC boosted its stake in shares of HCA Healthcare by 384.9% in the third quarter. Quest Partners LLC now owns 3,171 shares of the company’s stock valued at $1,289,000 after purchasing an additional 2,517 shares during the period. Pathstone Holdings LLC boosted its stake in shares of HCA Healthcare by 23.1% in the third quarter. Pathstone Holdings LLC now owns 27,589 shares of the company’s stock valued at $11,213,000 after purchasing an additional 5,175 shares during the period. Prospera Financial Services Inc boosted its stake in shares of HCA Healthcare by 204.2% in the third quarter. Prospera Financial Services Inc now owns 2,917 shares of the company’s stock valued at $1,186,000 after purchasing an additional 1,958 shares during the period. Finally, Banque Cantonale Vaudoise boosted its stake in shares of HCA Healthcare by 25.6% in the third quarter. Banque Cantonale Vaudoise now owns 12,187 shares of the company’s stock valued at $4,953,000 after purchasing an additional 2,481 shares during the period. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Jennifer Berres sold 9,533 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the completion of the transaction, the senior vice president now owns 15,412 shares in the company, valued at approximately $4,971,757.08. This trade represents a 38.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.60% of the company’s stock.

HCA Healthcare Stock Up 1.3 %

HCA stock opened at $334.42 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a fifty-two week low of $289.98 and a fifty-two week high of $417.14. The firm’s 50-day simple moving average is $320.53 and its 200 day simple moving average is $343.97. The stock has a market cap of $82.34 billion, a PE ratio of 15.22, a price-to-earnings-growth ratio of 1.10 and a beta of 1.68.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same quarter in the previous year, the business posted $5.90 EPS. As a group, sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be paid a dividend of $0.72 per share. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. The ex-dividend date is Monday, March 17th. This represents a $2.88 annualized dividend and a yield of 0.86%. HCA Healthcare’s dividend payout ratio (DPR) is presently 13.11%.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Wells Fargo & Company downgraded shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $400.00 to $320.00 in a research note on Monday, November 25th. Barclays reduced their price objective on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price objective on shares of HCA Healthcare in a research note on Monday, January 27th. Bank of America reduced their price objective on shares of HCA Healthcare from $380.00 to $370.00 and set a “buy” rating on the stock in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $380.00 target price on shares of HCA Healthcare in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.